Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors
- 10 June 2023
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 90, 117367
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- ACPYPE - AnteChamber PYthon Parser interfacEBMC Research Notes, 2012
- Open Babel: An open chemical toolboxJournal of Cheminformatics, 2011
- FMS-like tyrosine kinase 3 inhibitors: a patent reviewExpert Opinion on Therapeutic Patents, 2011
- Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cellsBioorganic & Medicinal Chemistry Letters, 2010
- Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivoEndocrine-Related Cancer, 2008
- Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitorBiochemical and Biophysical Research Communications, 2007
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesBlood, 2003
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997